Company profile
Telo Genomics Corp.
OTC: TDSGF · Healthcare · Medical - Diagnostics & Research
Canadian filerHQ Toronto, ONReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 20DQ —GM —SS 28
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, disclosure history · ↓ Piotroski F, return on equity
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.9M
Employees
8
as of 2026-08-25
Market cap
$1.8M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$1.9M-2.7M CAD2025
Operating income-$1.9M-2.7M CAD2025
Total assets$490.6k669.3k CAD2025
Liabilities$213.4k291.1k CAD2025
Equity$377.5k515.0k CAD2025
Revenue trend
FY2017 – FY2025 · USD
FY17
FY18
FY19
FY20
FY21
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Telo Genomics Corp.’s revenue?
Telo Genomics Corp. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Nu-Med Plus, Inc.23DGenprex, Inc.34DiMD Companies, Inc.47DLobe Sciences Ltd.42DDakshidin Corporation31DDecoy Therapeutics Inc.31DKey facts
CEOJohn Allen Farlinger
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersToronto, ON
ExchangeOTC: TDSGF
Employees8
IPO date2021-01-08
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.